Literature DB >> 28839972

Oligometastatic non-small cell lung cancer: is there a role for locoregional therapy?

Lawek Berzenji1, Paul E Van Schil1.   

Abstract

Entities:  

Year:  2017        PMID： 28839972      PMCID： PMC5542990          DOI： 10.21037/jtd.2017.06.108

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Local consolidative therapy may be beneficial in patients with oligometastatic non-small cell lung cancer.

Authors:  Mary Kay Barton
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

2.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).

Authors:  Atif J Khan; Par S Mehta; Thomas W Zusag; Philip D Bonomi; L Penfield Faber; Susan Shott; Ross A Abrams
Journal:  Radiother Oncol       Date:  2006-10-16       Impact factor: 6.280

3.  Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.

Authors:  Tetsuya Inoue; Norio Katoh; Hidefumi Aoyama; Rikiya Onimaru; Hiroshi Taguchi; Shunsuke Onodera; Satoshi Yamaguchi; Hiroki Shirato
Journal:  Jpn J Clin Oncol       Date:  2010-04-20       Impact factor: 3.019

4.  Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.

Authors:  Jeroen M H Hendriks; Marco J J H Grootenboers; Franz M N H Schramel; Wim J van Boven; Bernard Stockman; Cornelis A Seldenrijk; Pieter ten Broecke; Catherijne A J Knibbe; Peter Slee; Ernst De Bruijn; Renate Vlaeminck; Jos Heeren; Jan B Vermorken; Bart van Putte; Sander Romijn; Eric Van Marck; Paul E Y Van Schil
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

Review 5.  Surgery for oligometastatic disease in non-small-cell lung cancer.

Authors:  Paul E Van Schil; Jeroen M Hendriks; Laurens Carp; Patrick R Lauwers
Journal:  Expert Rev Anticancer Ther       Date:  2008-12       Impact factor: 4.512

6.  An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.

Authors:  Joseph K Salama; Steven J Chmura; Neil Mehta; Kamil M Yenice; Walter M Stadler; Everett E Vokes; Daniel J Haraf; Samuel Hellman; Ralph R Weichselbaum
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

7.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Authors:  Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

8.  Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases.

Authors:  Willem A den Hengst; Jeroen M H Hendriks; Bram Balduyck; Inez Rodrigus; Jan B Vermorken; Filip Lardon; Michel I M Versteegh; Jerry Braun; Hans Gelderblom; Franz M N H Schramel; Wim-Jan Van Boven; Bart P Van Putte; Özcan Birim; Alexander P W M Maat; Paul E Y Van Schil
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

9.  MicroRNA expression characterizes oligometastasis(es).

Authors:  Yves A Lussier; H Rosie Xing; Joseph K Salama; Nikolai N Khodarev; Yong Huang; Qingbei Zhang; Sajid A Khan; Xinan Yang; Michael D Hasselle; Thomas E Darga; Renuka Malik; Hanli Fan; Samantha Perakis; Matthew Filippo; Kimberly Corbin; Younghee Lee; Mitchell C Posner; Steven J Chmura; Samuel Hellman; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2011-12-13       Impact factor: 3.240

10.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316
View more
  2 in total

Review 1.  Surgical approaches in patients with oligometastatic non-small cell lung cancer.

Authors:  Luca Bertolaccini; Alessandro Pardolesi; Sergio Nicola Forti Parri; Barbara Bonfanti; Jury Brandolini; Piergiorgio Solli
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review.

Authors:  Luca Bertolaccini; Monica Casiraghi; Giulia Sedda; Filippo de Marinis; Lorenzo Spaggiari
Journal:  Transl Lung Cancer Res       Date:  2021-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.